Piramal Pharma JMFICS Post navigation Previous Previous post: Piramal Pharma has an ambitious roadmap to nearly double revenues in key segments by FY30. Buy for target price of ₹295 (53% upside): JMFICS Leave a Reply Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website Current ye@r * Leave this field empty